Translate this page into:
Hemi body irradiation: An economical way of palliation of pain in bone metastasis in advanced cancer
*Corresponding author: Dr. Santanu Pal. santanugm24@gmail.com
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Background: The primary aim of this prospective non-randomized study was to evaluate the effect of hemi-body irradiation (HBI) on pain and quality of life in cancer patients with extensive bone metastases. The secondary aim was to evaluate side-effects and cost-effectiveness of the treatment. Materials and Methods: Between March 2008 and December 2010, a total of 23 (male = 14, female = 9, median age = 60 years) diagnosed cases of metastatic cancer patients (prostate = 11, breast = 6, and lung = 6) received HBI, which was delivered as lower (n = 7) (dose = 8 Gy), upper (n = 8) (dose = 6 Gy), or sequential HBI (n = 8) with a Telecobalt unit (Theratron 780C). Among them, one lung cancer patient died at 2 months and one prostate cancer patient defaulted after the second follow-up. Thus, 21 patients (male = 13, female = 8, median age = 65 years) (prostatic cancer = 10, breast cancer = 6, and lung cancer = 5) were followed up for a minimum of 6 months. Evaluations were performed before and at 2, 4, 8, 16, and 24 weeks after treatment. Pain evaluation was done by Visual Analogue Scale (VAS), Verbal Rating Scale (VRS), Percentage of Pain Relief (PRR), and Global Pain Score (GPS). Toxicity was assessed by CTC v-3 toxicity scores in the medical record. Assessment of oral morphine consumption was done before and after radiation using paired t-test, and correlation analysis was also done with decrease of morphine consumption and reduction of pain score using statistical analysis. Results: Response (control of pain) was partial (PR) in 67% and complete (CR) in 22% of patients. For most patients, the pain control lasted throughout the follow-up period (6 months). From 66.66% patients requiring 13 or more Morphine (10 mg) tablets per day prior to HBI, none of the patients required to consume 13 or more Morphine (10 mg) tablets per day following HBI, which was correlated with significant reduction in various pain scores (P < 0.05). One way ANOVA with Dunnett′s Multiple Comparison Test (P < 0.05) was significant in VAS score changes, VRS score changes, PPR score changes, and GPS score changes. Along with the decrease in morphine tablets, the Linear Correlation of various scales for pain reduction like VAS, VRS, PPR, and GPS were significant. As such, the quality of life was better due to decreased pain and also, a decrease in the dose of analgesics. Grade 1 and 2 hematological toxicity and grade 1 diarrhea were observed as common side-effects. The average total cost of treatment including hospital stay, medicines, and radiation charges was around INR 400.00. Conclusion: This study shows that hemibody irradiation is not only an effective modality for palliation of severe bone pain in advanced cancer cases but also economical, involves short hospital stay, with acceptable side-effects, utilizes the simple Telecobalt machine, and is less cumbersome in comparison to other currently available pain palliation methods like oral morphine and radiopharmaceuticals.
Keywords
References
- Vakaet LA, Boterberg T. Pain Control by ionizing radiation of bone metastasis. Int J Dev Biol 2004;48:599-606.
- Ben-Josef E, Shamsa F, Williams AO, Proter AT. Radiotheraputic management of osseous metastases: A survey of current patterns of care. Int J Radiat Oncol Biol Phys 1998;40:915-21.
- Cook RJ, Major P. Methodology for treatment Evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001;93:534-8.
- Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters RS Jr, et al. Therapeutic guidelines for the treatment of bone metastasis: A report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med 2009;12:417-26.
- Fairchild A, Barnes E, Ghosh S, Ben-Josef E, Roos D, Hartsell W, et al. International patterns of practice in palliative radiotherapy for painful bone metastases: Evidence-based practice. Int J Radiat Oncol Biol Phys 2009;75:1501-10.
- Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: Single fraction versus multiple-fraction radiotherapy: A systematic review of randomised trials. Clin Oncol (R. Coll Radiol) 2003;15:345-52.
- Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: Single fraction versus multiple-fraction radiotherapy: A systematic review of the randomised trials. Cochrane Database Syst Rev 2004;2:CD004721.
- Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: A systematic review. J Clin Oncol 2007;25:1423-36.
- Wu JS, Wong R, Johnston M, Bezjak A, Whelan T. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594-605.
- Miszczyk L, Tukiendorf A, Gaborek A, Wydmariski J. An evaluation of half-body irradiation in the treatment of widespread, painful metastatic bone disease. Tumori 2008;94:813-21.
- Emanuel E J, Hauser J, Emanuel LL. Palliative and end of life care. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison′s Principles of Internal Medicine, 17 th ed., Vol 1. New York: McGraw Hill; 2008. 70-1.
- Serpell MG. Gabapentin in neuropathic pain syndromes: A randomized double-blind placebo-controlled trial. Pain 2002;99:557-66.
- Bennett M, Simpson KH. Gabapentin in treatment of neuropathic pain. Palliat Med 2004;18:5-11.
- Kalso E, Tasmuth T, Neuvonen PJ. Amitrytiline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996;64:293-302.
- Nag S, Shah V. Once-a-week lower hemibody irradiation (HBI) for metastatic cancers. Int J Radiat Oncol Biol Phys 1986;12:1003-5.
- Nseyo UO, Fontanesi J, Naftulin BN. Palliative hemibody irradiation in hormonally refractory metastatic prostate cancer. Urology 1989;34:76-9.
- Poulter CA, Cosmatos D, Rubin P, Urtasun R, Cooper JS, Kuske RR, et al. A report of RTOG 8206: A phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than localfield irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1992;23:207-14.
- Salazar OM, DaMotta NW, Bridgman SM, Cardiges NM, Slawson RG. Fractionated half-body irradiation for pain palliation in widely metastatic cancers: Comparison with single dose. Int J Radiat Oncol Biol Phys 1996;36:49-60.
- Dearnaley DP, Bayly RJ, A′Hern RP, Gadd J, Zivanovic MM, Levington VJ. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89. Clin Oncol, 1992;4:101-7.